title: Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
abstract: Since 2007, sorafenib is the new standard for the first-line treatment of advanced hepatocellular carcinoma (HCC), with proved effectiveness on survival, but no complete response. We encountered a case of complete and durable response after gemcitabine plus oxaliplatine (GEMOX) in a patient with metastatic HCC. The use of GEMOX was considered because the patient was young, without other liver disease, with bone and hepatic lesions, a rapidly progressive disease, and a poorly differentiated component on histological aspect. After 12 cycles of GEMOX, complete response occurs with disappearance of metastases and normalization of serum level of alpha-fetoprotein. This is the first case report of complete response of HCC to GEMOX. That is why the association of chemotherapy and molecular targeted therapies is a promising direction of research. Our report shows that another important challenge remains in the identification of predictive factors of response to standard chemotherapy or molecular targeted agents.
authors.affiliation: Fédération des Spécialités Digestives, Université Claude Bernard Lyon 1, Villeurbanne, France.
authors.forename: Gilles
authors.initials: G
authors.lastname: Boschetti
authors.forename: Thomas
authors.initials: T
authors.lastname: Walter
authors.forename: Valérie
authors.initials: V
authors.lastname: Hervieu
authors.forename: Philippe
authors.initials: P
authors.lastname: Cassier
authors.forename: Catherine
authors.initials: C
authors.lastname: Lombard-Bohas
authors.forename: Mustapha
authors.initials: M
authors.lastname: Adham
authors.forename: Jean-Yves
authors.initials: JY
authors.lastname: Scoazec
authors.forename: Jérôme
authors.initials: J
authors.lastname: Dumortier
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000473:pathology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D009536:Niacinamide / Q000031:analogs & derivatives; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D010534:Peritoneal Neoplasms / Q000556:secondary / Q000601:surgery; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D012074:Remission Induction; D000077157:Sorafenib; D000509:alpha-Fetoproteins / Q000032:analysis; D000093542:Gemcitabine
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D009944:Organoplatinum Compounds; D010671:Phenylurea Compounds; D011725:Pyridines; D000509:alpha-Fetoproteins; D000077150:Oxaliplatin; D003841:Deoxycytidine; D009536:Niacinamide; D000077157:Sorafenib; D000093542:Gemcitabine